Literature DB >> 23257621

Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.

K Rostásy1, S Mader, E M Hennes, K Schanda, V Gredler, A Guenther, A Blaschek, C Korenke, M Pritsch, D Pohl, O Maier, G Kuchukhidze, M Brunner-Krainz, T Berger, M Reindl.   

Abstract

BACKGROUND: Recently we showed that antibodies to myelin oligodendrocyte glycoprotein (MOG) can be found in aquaporin-4 (AQP4)-immunoglobulin (IgG) seronegative pediatric and adult patients with definite and high-risk neuromyelitis optica (NMO).
OBJECTIVE: The purpose of this study was to describe the clinical characteristics and temporal dynamics of MOG-IgG in AQP4-IgG seronegative pediatric patients presenting with definite NMO.
METHODS: Children with definite NMO who were referred for further testing of serum antibodies for AQP4 and MOG with a cell-based assay were included in this study. Clinical disease course, cerebrospinal fluid and magnetic resonance imaging (MRI) studies of these patients were reviewed.
RESULTS: Between 2008 and 2012 eight children who fulfilled the diagnostic criteria of definite NMO were recruited. Two children with definite NMO tested positive for AQP4-IgG but were negative for MOG-IgG antibodies. Three children had an absence of AQP4-IgG and MOG-IgG antibodies. Three children with definite NMO had high titers of serum MOG-IgG antibodies (≥1: 160), but no AQP4-directed humoral immune response. Longitudinal analysis of serum samples of the latter three children showed persisting high MOG-IgG titers over time.
CONCLUSION: Pediatric patients presenting with clinical symptoms and MRI findings highly suggestive of NMO but with high and persisting MOG-IgG antibody titers are most likely to represent a distinct subgroup of acute demyelinating diseases with important clinical and therapeutic implications.

Entities:  

Keywords:  AQP-4 antibodies; MOG antibodies; Neuromyelitis optica; children; optic neuritis

Mesh:

Substances:

Year:  2012        PMID: 23257621     DOI: 10.1177/1352458512470310

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  51 in total

1.  Clinical and MRI phenotype of children with MOG antibodies.

Authors:  Cristina Fernandez-Carbonell; David Vargas-Lowy; Alexander Musallam; Brian Healy; Katherine McLaughlin; Kai W Wucherpfennig; Tanuja Chitnis
Journal:  Mult Scler       Date:  2015-06-03       Impact factor: 6.312

Review 2.  Treatment of neuromyelitis optica: state-of-the-art and emerging therapies.

Authors:  Marios C Papadopoulos; Jeffrey L Bennett; Alan S Verkman
Journal:  Nat Rev Neurol       Date:  2014-08-12       Impact factor: 42.937

3.  MRI of the first event in pediatric acquired demyelinating syndromes with antibodies to myelin oligodendrocyte glycoprotein.

Authors:  Matthias Baumann; Astrid Grams; Tanja Djurdjevic; Eva-Maria Wendel; Christian Lechner; Bettina Behring; Astrid Blaschek; Katharina Diepold; Astrid Eisenkölbl; Joel Fluss; Michael Karenfort; Johannes Koch; Bahadir Konuşkan; Steffen Leiz; Andreas Merkenschlager; Daniela Pohl; Mareike Schimmel; Charlotte Thiels; Barbara Kornek; Kathrin Schanda; Markus Reindl; Kevin Rostásy
Journal:  J Neurol       Date:  2018-02-08       Impact factor: 4.849

Review 4.  Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research.

Authors:  Amy Waldman; Angelo Ghezzi; Amit Bar-Or; Yann Mikaeloff; Marc Tardieu; Brenda Banwell
Journal:  Lancet Neurol       Date:  2014-09       Impact factor: 44.182

5.  MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.

Authors:  Sven Jarius; Klemens Ruprecht; Ingo Kleiter; Nadja Borisow; Nasrin Asgari; Kalliopi Pitarokoili; Florence Pache; Oliver Stich; Lena-Alexandra Beume; Martin W Hümmert; Marius Ringelstein; Corinna Trebst; Alexander Winkelmann; Alexander Schwarz; Mathias Buttmann; Hanna Zimmermann; Joseph Kuchling; Diego Franciotta; Marco Capobianco; Eberhard Siebert; Carsten Lukas; Mirjam Korporal-Kuhnke; Jürgen Haas; Kai Fechner; Alexander U Brandt; Kathrin Schanda; Orhan Aktas; Friedemann Paul; Markus Reindl; Brigitte Wildemann
Journal:  J Neuroinflammation       Date:  2016-09-27       Impact factor: 8.322

Review 6.  The spectrum of MOG autoantibody-associated demyelinating diseases.

Authors:  Markus Reindl; Franziska Di Pauli; Kevin Rostásy; Thomas Berger
Journal:  Nat Rev Neurol       Date:  2013-06-25       Impact factor: 42.937

Review 7.  Anti-myelin oligodendrocyte glycoprotein antibodies: Magnetic resonance imaging findings in a case series and a literature review.

Authors:  Michaela Cellina; Vincenza Fetoni; Matteo Ciocca; Marta Pirovano; Giancarlo Oliva
Journal:  Neuroradiol J       Date:  2017-04-05

8.  The history of neuromyelitis optica.

Authors:  Sven Jarius; Brigitte Wildemann
Journal:  J Neuroinflammation       Date:  2013-01-15       Impact factor: 8.322

9.  Anti-MOG Antibody Seropositive Neuromyelitis Optica: A Rare Pediatric Case.

Authors:  Gonca Koç; Nurettin Bayram; Ahmet Sami Güven; Doğan Bahadır İnan; Ali Kaya
Journal:  Noro Psikiyatr Ars       Date:  2019-02-05       Impact factor: 1.339

10.  'Spinal amaurosis' (1841). On the early contribution of Edward Hocken to the concept of neuromyelitis optica.

Authors:  S Jarius; B Wildemann
Journal:  J Neurol       Date:  2013-12-24       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.